Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
–News Direct– Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion with news of the publication of extended data from the Phase 2 EMPhASIS trial of…